Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. Patient-derived xenografts (PDXs) are used for various aspects of translational research including preclinical in vivo validation of experimental treatment approaches. While it was repeatedly demonstrated that PDXs keep majority of somatic mutations with the primary lymphoma samples, from which they were derived, the composition of PDX tumor microenvironment (TME) has not been extensively studied. We carried out a comparative genetic and histopathological study of 15 PDX models derived from patients with various types of NHL including diffuse large B-cell lymphoma (DLBCL; n = 7), Burkitt lymphoma (BL; n = 1), mantle cell lymphoma (MCL; n = 2), and peripheral T-cell lymphomas (PTCL; n = 5). Whole exome sequencing (WES) of the PDXs and primary lymphoma cells was implemented in 13 out of 15 cases with available DNA samples. Standard immunohistochemistry (IHC) was used to analyze the composition of PDX TME. WES data confirmed that PDXs maintained the genetic heterogeneity with the original primary lymphoma cells. In contrast, IHC analysis revealed the following recurrently observed alterations in the composition of PDX tumors: more blastoid lymphoma cell morphology, increased proliferation rate, lack of non-malignant cellular components including T cells and (human or murine) macrophages, and significantly lower intratumoral microvessel density and microvessel area composed of murine vessels. In addition, PDX tumors derived from T-NHL displayed additional differences compared to the primary lymphoma samples including markedly lower desmoplasia (i.e., the extent of both reticular and collagen fibrosis), loss of expression of cytotoxic granules (i.e., perforin, TIA, granzyme B), or loss of expression of T-cell specific antigens (i.e., CD3, CD4, CD8). Our data suggest that despite keeping the same genetic profiles, PDX models of aggressive NHL do not recapitulate the microenvironmental heterogeneity of the original lymphomas. These findings have implications on the relevance of PDX models in the context of preclinical research.

1st Department of Medicine Hematology University General Hospital Prague and 1st Faculty of Medicine Charles University Prague Czech Republic

CLIP Childhood Leukaemia Investigation Prague Department of Pediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Histology and Embryology and Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Pathology University General Hospital Prague and 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood127, 2375–2390 (2016). PubMed PMC

Swerdlow, S. H. & Cook, J. R. As the world turns, evolving lymphoma classifications-past, present and future. Hum. Pathol.10.1016/j.humpath.2019.08.019 (2019). PubMed

Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L. & Li, P. Current status and perspectives of patient-derived xenograft models in cancer research. J. Hematol. Oncol.10, 106 (2017). PubMed PMC

Sugimoto, K., Hayakawa, F., Shimada, S., Morishita, T., Shimada, K., Katakai, T. et al. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci. Rep.5, 13054 (2015). PubMed PMC

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell29, 574–586 (2016). PubMed PMC

Chapuy, B., Cheng, H., Watahiki, A., Ducar, M. D., Tan, Y., Chen, L. et al. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood127, 2203–2213 (2016). PubMed PMC

Burack, W. R., Spence, J. M., Spence, J. P., Spence, S. A., Rock, P. J., Shenoy, G. N. et al. Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment. Blood Adv.1, 1263–1273 (2017). PubMed PMC

Zhang, L., Nomie, K., Zhang, H., Bell, T., Pham, L., Kadri, S. et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin. Cancer Res.23, 4212–4223 (2017). PubMed PMC

Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell21, 309–322 (2012). PubMed

Shain, K. H., Dalton, W. S. & Tao, J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene34, 4673–4682 (2015). PubMed PMC

McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov.12, 217–228 (2013). PubMed

Prukova, D., Andera, L., Nahacka, Z., Karolova, J., Svaton, M., Klanova, M. et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin. Cancer Res. 25, 4455–4465 (2019). PubMed

Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med.378, 1396–1407 (2018). PubMed PMC

Pasqualucci, L. & Dalla-Favera, R. Genetics of diffuse large B-cell lymphoma. Blood131, 2307–2319 (2018). PubMed PMC

Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell171, 481–494.e415 (2017). PubMed PMC

Dubois, S., Viailly, P. J., Mareschal, S., Bohers, E., Bertrand, P., Ruminy, P. et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res.22, 2919–2928 (2016). PubMed

Karube, K., Enjuanes, A., Dlouhy, I., Jares, P., Martin-Garcia, D., Nadeu, F. et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia32, 675–684 (2018). PubMed PMC

Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet.43, 830–837 (2011). PubMed PMC

Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA.110, 1398–1403 (2013). PubMed PMC

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA.109, 3879–3884 (2012). PubMed PMC

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature476, 298–303 (2011). PubMed PMC

Zhang, J., Jima, D., Moffitt, A. B., Liu, Q., Czader, M., Hsi, E. D. et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood123, 2988–2996 (2014). PubMed PMC

Bea, S., Valdes-Mas, R., Navarro, A., Salaverria, I., Martin-Garcia, D., Jares, P. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl Acad. Sci. USA. 110, 18250–18255 (2013). PubMed PMC

Yang, P., Zhang, W., Wang, J., Liu, Y., An, R. & Jing, H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther.10.1038/s41417-018-0022-5 (2018). PubMed

Royo, C., Salaverria, I., Hartmann, E. M., Rosenwald, A., Campo, E. & Beà, S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin. Cancer Biol.21, 322–334 (2011). PubMed

Wu, C., de Miranda, N. F., Chen, L., Wasik, A. M., Mansouri, L., Jurczak, W. et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget7, 38180–38190 (2016). PubMed PMC

Ahmed, M., Zhang, L., Nomie, K., Lam, L. & Wang, M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget7, 58638–58648 (2016). PubMed PMC

Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N. et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell27, 516–532 (2015). PubMed PMC

Larose, H., Prokoph, N., Matthews, J. D., Schlederer, M., Högler, S., Alsulami, A. F. et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica106, 1693–1704 (2021). PubMed PMC

Odejide, O., Weigert, O., Lane, A. A., Toscano, D., Lunning, M. A., Kopp, N. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood123, 1293–1296 (2014). PubMed PMC

Palomero, T., Couronné, L., Khiabanian, H., Kim, M. Y., Ambesi-Impiombato, A., Perez-Garcia, A. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet.46, 166–170 (2014). PubMed PMC

Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet.46, 171–175 (2014). PubMed

Vallois, D., Dobay, M. P., Morin, R. D., Lemonnier, F., Missiaglia, E., Juilland, M. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood128, 1490–1502 (2016). PubMed

Watatani, Y., Sato, Y., Miyoshi, H., Sakamoto, K., Nishida, K., Gion, Y. et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia33, 2867–2883 (2019). PubMed

Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E. J. et al. Molecular diagnosis of Burkitt’s lymphoma. N. Engl J. Med.354, 2431–2442 (2006). PubMed

Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet.44, 1321–1325 (2012). PubMed PMC

López, C., Kleinheinz, K., Aukema, S. M., Rohde, M., Bernhart, S. H., Hübschmann, D. et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat. Commun.10, 1459 (2019). PubMed PMC

Panea, R. I., Love, C. L., Shingleton, J. R., Reddy, A., Bailey, J. A., Moormann, A. M. et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood134, 1598–1607 (2019). PubMed PMC

Penther, D., Viailly, P. J., Latour, S., Etancelin, P., Bohers, E., Vellemans, H. et al. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. Genes Chromosomes Cancer58, 595–601 (2019). PubMed PMC

Richter, J., Schlesner, M., Hoffmann, S., Kreuz, M., Leich, E., Burkhardt, B. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet.44, 1316–1320 (2012). PubMed

Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature490, 116–120 (2012). PubMed PMC

Wagener, R., Seufert, J., Raimondi, F., Bens, S., Kleinheinz, K., Nagel, I. et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood133, 962–966 (2019). PubMed PMC

Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol.12, e1004873 (2016). PubMed PMC

Tibshirani, R. & Wang, P. Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics9, 18–29 (2008). PubMed

Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. Bioinformatics30, 2811–2812 (2014). PubMed

Keša, P., Pokorná, E., Grajciarová, M., Tonar, Z., Vočková, P., Trochet, P. et al. Quantitative in vivo monitoring of hypoxia and vascularization of patient-derived murine xenografts of mantle cell lymphoma using photoacoustic and ultrasound imaging. Ultrasound Med. Biol.47, 1099–1107 (2021). PubMed

Kolinko, Y., Malečková, A., Kochová, P., Grajciarová, M., Blassová, T., Kural, T. et al. Using virtual microscopy for the development of sampling strategies in quantitative histology and design-based stereology. Anat. Histol. Embryol.10.1111/ahe.12765 (2021). PubMed

Tonar, Z., Egger, G. F., Witter, K. & Wolfesberger, B. Quantification of microvessels in canine lymph nodes. Microsc. Res. Tech.71, 760–772 (2008). PubMed

Veselá, P., Tonar, Z., Sálek, D., Vokurka, S., Trněný, M., Kodet, R. et al. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch.465, 587–597 (2014). PubMed

Petrakis, G., Veloza, L., Clot, G., Gine, E., Gonzalez-Farre, B., Navarro, A. et al. Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma. Histopathology75, 704–714 (2019). PubMed

Gundersen, H. J. Estimators of the number of objects per area unbiased by edge effects. Microsc Acta81, 107–117 (1978). PubMed

Forde, S., Matthews, J. D., Jahangiri, L., Lee, L. C., Prokoph, N., Malcolm, T. I. M. et al. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. Br. J. Haematol.192, 354–365 (2021). PubMed

Woo, X. Y., Giordano, J., Srivastava, A., Zhao, Z. M., Lloyd, M. W., de Bruijn, R. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet.53, 86–99 (2021). PubMed PMC

Choi, Y. Y., Lee, J. E., Kim, H., Sim, M. H., Kim, K. K., Lee, G. et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci. Rep.6, 22172 (2016). PubMed PMC

Di Noia, J. M. & Neuberger, M. S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem.76, 1–22 (2007). PubMed

Ben-David, U., Ha, G., Tseng, Y. Y., Greenwald, N. F., Oh, C., Shih, J. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet.49, 1567–1575 (2017). PubMed PMC

Klanova, M., Soukup, T., Jaksa, R., Molinsky, J., Lateckova, L., Maswabi, B. C. et al. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab. Invest.94, 806–817 (2014). PubMed

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma

First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma

Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status